Biomarin Pharmaceutical Stock Probability Of Bankruptcy

BMRN Stock

USD 71.53 0.46 0.64%

Biomarin Pharmaceutical's chance of distress is below 1% at this time. The company is very unlikely to encounter any financial straits in the next two years. Odds of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Biomarin balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Biomarin Pharmaceutical Piotroski F Score and Biomarin Pharmaceutical Altman Z Score analysis.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

As of the 26th of March 2025, Market Cap is likely to drop to about 8 B. In addition to that, Enterprise Value is likely to drop to about 9.8 B

Biomarin Pharmaceutical Company odds of distress Analysis

Biomarin Pharmaceutical's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Biomarin Pharmaceutical Probability Of Bankruptcy

Less than 1%

Most of Biomarin Pharmaceutical's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomarin Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Biomarin Pharmaceutical probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Biomarin Pharmaceutical odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Biomarin Pharmaceutical financial health.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

6.449

Earnings Share

2.21

Revenue Per Share

15.018

Quarterly Revenue Growth

0.156

Return On Assets

0.0515

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Term Debt	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Good Will	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.03	-0.11	0.4	0.95	0.78	0.97	0.41	0.46	-0.14	0.77	0.64	0.98	0.42	0.79	0.97	0.84	0.9	0.73	-0.48	0.8	0.67	0.74
Total Stockholder Equity	0.99		-0.09	0.01	0.31	0.97	0.68	0.97	0.31	0.37	-0.22	0.69	0.56	0.97	0.37	0.73	0.99	0.82	0.85	0.7	-0.46	0.85	0.73	0.82
Net Debt	0.03	-0.09		-0.64	0.38	-0.16	0.54	-0.09	0.55	0.65	0.04	0.34	0.42	0.04	0.0	0.39	-0.12	0.06	0.26	0.19	-0.16	-0.21	-0.37	-0.47
Retained Earnings	-0.11	0.01	-0.64		-0.84	0.09	-0.57	-0.06	-0.76	-0.65	-0.35	-0.55	-0.44	-0.22	-0.39	-0.5	0.1	-0.03	-0.39	-0.26	0.53	0.44	0.47	0.45
Accounts Payable	0.4	0.31	0.38	-0.84		0.26	0.66	0.35	0.79	0.5	0.4	0.66	0.33	0.51	0.51	0.71	0.21	0.2	0.61	0.52	-0.54	-0.12	-0.21	-0.11
Net Receivables	0.95	0.97	-0.16	0.09	0.26		0.6	0.96	0.18	0.29	-0.21	0.61	0.41	0.93	0.28	0.64	0.97	0.75	0.79	0.62	-0.4	0.86	0.72	0.85
Total Liab	0.78	0.68	0.54	-0.57	0.66	0.6		0.71	0.68	0.71	0.18	0.92	0.82	0.78	0.48	0.86	0.63	0.76	0.89	0.68	-0.41	0.44	0.28	0.18
Total Current Assets	0.97	0.97	-0.09	-0.06	0.35	0.96	0.71		0.27	0.45	-0.11	0.72	0.58	0.96	0.41	0.69	0.96	0.82	0.84	0.62	-0.44	0.8	0.7	0.78
Intangible Assets	0.41	0.31	0.55	-0.76	0.79	0.18	0.68	0.27		0.58	0.22	0.65	0.55	0.48	0.42	0.78	0.2	0.29	0.58	0.57	-0.51	-0.1	-0.11	-0.14
Short Term Investments	0.46	0.37	0.65	-0.65	0.5	0.29	0.71	0.45	0.58		-0.08	0.58	0.66	0.49	0.24	0.61	0.33	0.43	0.59	0.31	-0.51	0.08	0.09	-0.01
Short Term Debt	-0.14	-0.22	0.04	-0.35	0.4	-0.21	0.18	-0.11	0.22	-0.08		0.18	0.04	-0.13	0.41	-0.05	-0.28	-0.07	-0.09	0.03	0.28	-0.35	-0.42	-0.32
Common Stock	0.77	0.69	0.34	-0.55	0.66	0.61	0.92	0.72	0.65	0.58	0.18		0.79	0.78	0.37	0.81	0.61	0.72	0.86	0.66	-0.44	0.42	0.35	0.2
Long Term Debt	0.64	0.56	0.42	-0.44	0.33	0.41	0.82	0.58	0.55	0.66	0.04	0.79		0.62	0.41	0.63	0.53	0.74	0.69	0.37	-0.26	0.36	0.36	0.12
Property Plant Equipment	0.98	0.97	0.04	-0.22	0.51	0.93	0.78	0.96	0.48	0.49	-0.13	0.78	0.62		0.44	0.82	0.93	0.78	0.91	0.7	-0.56	0.71	0.6	0.7
Current Deferred Revenue	0.42	0.37	0.0	-0.39	0.51	0.28	0.48	0.41	0.42	0.24	0.41	0.37	0.41	0.44		0.52	0.36	0.48	0.53	0.51	-0.38	0.13	0.08	0.12
Good Will	0.79	0.73	0.39	-0.5	0.71	0.64	0.86	0.69	0.78	0.61	-0.05	0.81	0.63	0.82	0.52		0.67	0.72	0.94	0.8	-0.59	0.46	0.4	0.26
Net Tangible Assets	0.97	0.99	-0.12	0.1	0.21	0.97	0.63	0.96	0.2	0.33	-0.28	0.61	0.53	0.93	0.36	0.67		0.82	0.82	0.65	-0.41	0.89	0.78	0.84
Long Term Debt Total	0.84	0.82	0.06	-0.03	0.2	0.75	0.76	0.82	0.29	0.43	-0.07	0.72	0.74	0.78	0.48	0.72	0.82		0.85	0.62	-0.25	0.8	0.78	0.48
Capital Surpluse	0.9	0.85	0.26	-0.39	0.61	0.79	0.89	0.84	0.58	0.59	-0.09	0.86	0.69	0.91	0.53	0.94	0.82	0.85		0.77	-0.56	0.63	0.54	0.41
Long Term Investments	0.73	0.7	0.19	-0.26	0.52	0.62	0.68	0.62	0.57	0.31	0.03	0.66	0.37	0.7	0.51	0.8	0.65	0.62	0.77		-0.58	0.53	0.34	0.4
Short Long Term Debt	-0.48	-0.46	-0.16	0.53	-0.54	-0.4	-0.41	-0.44	-0.51	-0.51	0.28	-0.44	-0.26	-0.56	-0.38	-0.59	-0.41	-0.25	-0.56	-0.58		-0.1	-0.08	-0.23
Net Invested Capital	0.8	0.85	-0.21	0.44	-0.12	0.86	0.44	0.8	-0.1	0.08	-0.35	0.42	0.36	0.71	0.13	0.46	0.89	0.8	0.63	0.53	-0.1		0.88	0.8
Net Working Capital	0.67	0.73	-0.37	0.47	-0.21	0.72	0.28	0.7	-0.11	0.09	-0.42	0.35	0.36	0.6	0.08	0.4	0.78	0.78	0.54	0.34	-0.08	0.88		0.69
Capital Stock	0.74	0.82	-0.47	0.45	-0.11	0.85	0.18	0.78	-0.14	-0.01	-0.32	0.2	0.12	0.7	0.12	0.26	0.84	0.48	0.41	0.4	-0.23	0.8	0.69

	2020	2021	2022	2023	2024	2025 (projected)
Return On Assets	0.15	(0.0107)	0.0222	0.0245	0.0611	0.0641
Gross Profit Margin	0.72	0.75	0.77	0.76	0.8	1.01
Net Debt	426.0M	491.8M	358.5M	340.6M	(340.1M)	(323.1M)
Total Current Liabilities	492.5M	539.8M	588.9M	1.2B	607.0M	317.7M
Non Current Liabilities Total	1.2B	1.2B	1.2B	713.0M	724.0M	594.3M
Total Assets	5.8B	6.0B	6.4B	6.8B	7.0B	7.3B
Total Current Assets	2.3B	2.3B	2.8B	3.0B	3.2B	3.4B
Total Cash From Operating Activities	85.4M	304.5M	175.9M	159.3M	572.8M	601.5M

	Return On Equity	0.0805
	Return On Asset	0.0515
	Profit Margin	0.15 %
	Operating Margin	0.34 %
	Current Valuation	13.11 B
	Shares Outstanding	190.78 M
	Shares Owned By Insiders	0.96 %
	Shares Owned By Institutions	98.62 %
	Number Of Shares Shorted	4.47 M
	Price To Earning	220.73 X
	Price To Book	2.41 X
	Price To Sales	4.81 X
	Revenue	2.85 B
	Gross Profit	2.27 B
	EBITDA	650.53 M
	Net Income	426.86 M
	Cash And Equivalents	1.27 B
	Cash Per Share	6.85 X
	Total Debt	602.71 M
	Debt To Equity	0.24 %
	Current Ratio	5.15 X
	Book Value Per Share	29.66 X
	Cash Flow From Operations	572.84 M
	Short Ratio	2.98 X
	Earnings Per Share	2.21 X
	Price To Earnings To Growth	0.49 X
	Target Price	96.72
	Number Of Employees	3.04 K
	Beta	0.33
	Market Capitalization	13.73 B
	Total Asset	6.99 B
	Retained Earnings	(194.69 M)
	Working Capital	2.63 B
	Current Asset	1.09 B
	Current Liabilities	445.46 M
	Net Asset	6.99 B

Biomarin Pharmaceutical Stock Probability Of Bankruptcy

Biomarin Pharmaceutical Company odds of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Biomarin Pharmaceutical Probability Of Bankruptcy

Biomarin Probability Of Bankruptcy Driver Correlations

Biomarin Probability Of Bankruptcy Peer Comparison

Biomarin Pharmaceutical Main Bankruptcy Drivers

Biomarin Pharmaceutical ESG Sustainability

Biomarin Fundamentals

About Biomarin Pharmaceutical Fundamental Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY